FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. What is presented is a completely human monoclonal antibody, which binds insulin-like growth factor-II (IGF-II) and has a cross responsiveness to IGF-I, as well as its antigen-binding fragment. There are disclosed a nucleic acid molecule coding an antibody according to the invention, a vector and a host cell for the expression of the antibody according the invention. There are described a pharmaceutical composition, as well as conjugates for treating and diagnosing malignant tumour, using the antibody according to the invention in preparing the therapeutic agent and a method for determining IGF-II and IGF-I levels in a patient's sample.
EFFECT: present invention can find further application in cancer therapy.
16 cl, 27 ex, 18 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING PROTEINS, SPECIFIC WITH RESPECT TO INSULIN-LIKE GROWTH FACTORS, AND THEIR APPLICATION | 2006 |
|
RU2492185C2 |
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| ANTI-GARP-TGF-β-ANTIBODIES | 2018 |
|
RU2767784C2 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| RECOVERED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND METHOD OF INHIBITION OF PSMA-EXPRESSING CELL GROWTH | 2006 |
|
RU2421466C2 |
| ANTIGEN-BINDING PROTEINS | 2012 |
|
RU2607038C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| DLL4 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415869C2 |
